Nektar Therapeutics reports results for the quarter ended September 30 - Earnings Summary

• Nektar Therapeutics reported a quarterly adjusted loss of $1.63​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.87. The mean expectation of fifteen analysts for the quarter was for a loss of $2.07 per share. Wall Street expected results to range from $-3.07 to $-1.71 per share.

• Revenue fell 20.4% to $9.39 million from a year ago; analysts expected $10.27 million.

• Nektar Therapeutics's reported EPS for the quarter was a loss of $1.63​.

• The company reported a quarterly loss of $55.65 million.

• Nektar Therapeutics shares had fallen by 36.5% this quarter and lost 9.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 38.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Nektar Therapeutics is $150.00, about 75.2% above its last closing price of $37.25

This summary was machine generated from LSEG data November 12 at 11:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)